Randomized Controlled Trial of the Gastrin/CCK2 Receptor Antagonist Netazepide in Patients with Barrett's Esophagus

Treatment of patients with Barrett's esophagus with a gastrin/CCK2 receptor antagonist did not have obvious chemopreventive effects. Hypergastrinemia has been associated with high-grade dysplasia and adenocarcinoma in patients with Barrett's esophagus, and experimental studies suggest proinflammatory and proneoplastic effects of gastrin on Barrett's esophagus. This is of potential concern, as patients with Barrett's esophagus are treated with medications that suppress gastric acid production, resulting in increased physiologic levels of gastrin. We aimed to determine whether treatment with the novel gastrin/CCK2 receptor antagonist netazepide reduces expression of markers associated with inflammation and neoplasia in Barrett's esophagus. This was a randomized, double-blind, placebo-controlled trial of netazepide in patients with Barrett's esophagus without dysplasia. Subjects were treated for 12 weeks, with endoscopic assessment at baseline and at end of treatment. The primary outcome was within-individual change in cellular proliferation as assessed by Ki67. Secondary analyses included changes in gene expression, assessed by RNA-sequencing, and safety and tolerability. A total of 20 subjects completed the study and were included in the analyses. There was no difference between arms in mean change in cellular proliferation (netazepide: +35.6 Ki67+ cells/mm2, SD 620.7; placebo: +307.8 Ki67+ cells/mm2, SD 640.3; P = 0.35). Netazepide treatment resulted in increased expression of genes related to gastric phenotype (TFF2, MUC5B) and certain cancer-associated markers (REG3A, PAX9, MUC1), and decreased expression of intestinal markers MUC2, FABP1, FABP2, and CDX1. No serious adverse events related to study drug occurred. The gastrin/CCK2 receptor antagonist netazepide did not reduce cellular proliferation in patients with nondysplastic Barrett's esophagus. Further research should focus on the biological effects of gastrin in Barrett's esophagus. Prevention Relevance: Treatment of patients with Barrett's esophagus with a gastrin/CCK2 receptor antagonist did not have obvious chemopreventive effects.

[1]  G. Ginsberg,et al.  Notch Signaling Mediates Differentiation in Barrett's Esophagus and Promotes Progression to Adenocarcinoma. , 2020, Gastroenterology.

[2]  A. Bass,et al.  Hormonal Suppression of Stem Cells Inhibits Symmetric Cell Division and Gastric Tumorigenesis. , 2020, Cell stem cell.

[3]  A. Auton,et al.  Gastroesophageal reflux GWAS identifies risk loci that also associate with subsequent severe esophageal diseases , 2019, Nature Communications.

[4]  Patrick Breheny,et al.  p-Value Histograms: Inference and Diagnostics , 2018, High-throughput.

[5]  P. Moayyedi,et al.  Esomeprazole and aspirin in Barrett's oesophagus (AspECT): a randomised factorial trial , 2018, The Lancet.

[6]  A. Chak,et al.  The Effect of Endoscopic Surveillance in Patients With Barrett's Esophagus: A Systematic Review and Meta-analysis. , 2018, Gastroenterology.

[7]  F. Campbell,et al.  Netazepide, a gastrin/cholecystokinin‐2 receptor antagonist, can eradicate gastric neuroendocrine tumours in patients with autoimmune chronic atrophic gastritis , 2017, British journal of clinical pharmacology.

[8]  K. Strauch,et al.  Goblet Cell Ratio in Combination with Differentiation and Stem Cell Markers in Barrett Esophagus Allow Distinction of Patients with and without Esophageal Adenocarcinoma , 2016, Cancer Prevention Research.

[9]  R. Fossmark,et al.  The gastrin receptor antagonist netazepide (YF476) in patients with type 1 gastric enterochromaffin-like cell neuroendocrine tumours: review of long-term treatment , 2016, European journal of gastroenterology & hepatology.

[10]  Kenneth K Wang,et al.  Gastrin stimulates a cholecystokinin-2-receptor-expressing cardia progenitor cell and promotes progression of Barrett's-like esophagus , 2016, Oncotarget.

[11]  M. Vieth,et al.  Systematic review: the effects of long‐term proton pump inhibitor use on serum gastrin levels and gastric histology , 2015, Alimentary pharmacology & therapeutics.

[12]  Patricia L. Blount,et al.  High Goblet Cell Count Is Inversely Associated with Ploidy Abnormalities and Risk of Adenocarcinoma in Barrett’s Esophagus , 2015, PloS one.

[13]  Nicholas J Shaheen,et al.  Epidemiology of Barrett's Esophagus and Esophageal Adenocarcinoma. , 2015, Gastroenterology clinics of North America.

[14]  J. Black,et al.  Effect of netazepide, a gastrin/CCK2 receptor antagonist, on gastric acid secretion and rabeprazole-induced hypergastrinaemia in healthy subjects. , 2015, British journal of clinical pharmacology.

[15]  Marie-Liesse Asselin-Labat,et al.  Why weight? Modelling sample and observational level variability improves power in RNA-seq analyses , 2015, Nucleic acids research.

[16]  N. Marcon,et al.  Metformin does not reduce markers of cell proliferation in esophageal tissues of patients with Barrett's esophagus. , 2015, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[17]  Matthew E. Ritchie,et al.  limma powers differential expression analyses for RNA-sequencing and microarray studies , 2015, Nucleic acids research.

[18]  S. Dudoit,et al.  Normalization of RNA-seq data using factor analysis of control genes or samples , 2014, Nature Biotechnology.

[19]  Björn Usadel,et al.  Trimmomatic: a flexible trimmer for Illumina sequence data , 2014, Bioinform..

[20]  H. Barr,et al.  The stem cell organisation, and the proliferative and gene expression profile of Barrett's epithelium, replicates pyloric-type gastric glands , 2014, Gut.

[21]  Charity W. Law,et al.  voom: precision weights unlock linear model analysis tools for RNA-seq read counts , 2014, Genome Biology.

[22]  Diane D. Liu,et al.  Phase Ib Randomized, Double-Blinded, Placebo-Controlled, Dose Escalation Study of Polyphenon E in Patients with Barrett's Esophagus , 2013, Cancer Prevention Research.

[23]  S. Warrington,et al.  Effect of repeated doses of netazepide, a gastrin receptor antagonist, omeprazole and placebo on 24 h gastric acidity and gastrin in healthy subjects. , 2013, British journal of clinical pharmacology.

[24]  F. Campbell,et al.  Netazepide, a Gastrin Receptor Antagonist, Normalises Tumour Biomarkers and Causes Regression of Type 1 Gastric Neuroendocrine Tumours in a Nonrandomised Trial of Patients with Chronic Atrophic Gastritis , 2013, PloS one.

[25]  Wei Shi,et al.  featureCounts: an efficient general purpose program for assigning sequence reads to genomic features , 2013, Bioinform..

[26]  G. Qvigstad,et al.  Treatment of gastric carcinoids type 1 with the gastrin receptor antagonist netazepide (YF476) results in regression of tumours and normalisation of serum chromogranin A , 2012, Alimentary pharmacology & therapeutics.

[27]  A. Johnston,et al.  Single oral doses of netazepide (YF476), a gastrin receptor antagonist, cause dose‐dependent, sustained increases in gastric pH compared with placebo and ranitidine in healthy subjects , 2012, Alimentary pharmacology & therapeutics.

[28]  G. Smyth,et al.  Camera: a competitive gene set test accounting for inter-gene correlation , 2012, Nucleic acids research.

[29]  A. Neugut,et al.  Dating the Rise of Esophageal Adenocarcinoma: Analysis of Connecticut Tumor Registry Data, 1940–2007 , 2010, Cancer Epidemiology, Biomarkers & Prevention.

[30]  W. Tsai,et al.  Elevated Serum Gastrin Is Associated With a History of Advanced Neoplasia in Barrett's Esophagus , 2010, The American Journal of Gastroenterology.

[31]  A. Shar,et al.  Secondary chemoprevention of Barrett's esophagus with celecoxib: results of a randomized trial. , 2007, Journal of the National Cancer Institute.

[32]  L. Lovat,et al.  Gastrin-Induced Cyclooxygenase-2 Expression in Barrett’s Carcinogenesis , 2004, Clinical Cancer Research.

[33]  D. Thompson,et al.  Gastrin induces proliferation in Barrett's metaplasia through activation of the CCK2 receptor. , 2003, Gastroenterology.

[34]  A. Jemal,et al.  Cancer statistics, 2019 , 2019, CA: a cancer journal for clinicians.

[35]  S. Warrington,et al.  Randomised trial of the effect of a gastrin/CCK2 receptor antagonist on esomeprazole-induced hypergastrinaemia: evidence against rebound hyperacidity , 2016, European Journal of Clinical Pharmacology.

[36]  Thomas R. Gingeras,et al.  STAR: ultrafast universal RNA-seq aligner , 2013, Bioinform..

[37]  M. Vieth,et al.  Cardiac rather than intestinal-type background in endoscopic resection specimens of minute Barrett adenocarcinoma. , 2009, Human pathology.

[38]  Alex E. Lash,et al.  Gene Expression Omnibus: NCBI gene expression and hybridization array data repository , 2002, Nucleic Acids Res..

[39]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.